Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thiogenesis Therapeutics Corp. has partnered with UC San Diego to advance a Phase 2 clinical trial for TTI-0102, a promising treatment for pediatric NASH, a severe liver condition with no current approved medications. The treatment, leveraging an existing drug’s safety data, aims to alleviate liver inflammation and scarring in children, with plans to assess improvements and safety over a 12-week trial period.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money